EnGeneIC logo

Publications

Oct 2024
Millionaire Asia on EnGeneIC: ‘a game-changer in cancer treatment’
Oct 2024
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate
Mar 2024
A Phase 1 Study of Intravenous EGFR‑ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor
Jan 2024
Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
Jan 2023
Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern.
Mar 2020
Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocell.
Mar 2019
RET kinase-regulated microRNA-153-3p improves therapeutic efficacy in medullary thyroid carcinoma
May 2018
Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma
Dec 2017
Translational applications of microRNAs in cancer, and therapeutic Implications
Oct 2017
Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumor growth in mouse xenograft models
Sept 2017
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma a first-in-man phase 1 open-label dose
May 2016
Clinical Development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer
April 2016
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model
December 2015
A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells
December 2015
First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma
October 2015
microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma
June 2015
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma
June 2015
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma
Jan/Feb 2015
Nanocell targeting using engineered bispecific antibodies
December 2013
Restoring expression of miR-16 a novel approach to therapy for malignant pleural mesothelioma
2013
New delivery option for anticancer drugs demonstrated in a clinical trial
February 2013
Targeted Nanoparticle Delivery of Doxorubicin Into Placental Tissues to Treat Ectopic Pregnancies
December 2011
Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy
August 2009
Special Delivery
2009
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug
2009
Minicells overcome tumor drug-resistance
September 2007
Bacterially Derived Nanocells for Tumor Targeted Delivery of Chemotherapeutics and Cell Cycle Inhibitors
July 2007
Minicells deliver lethal load to tumors
May 2007
Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics